Modulation of Insulin Sensitivity by Betaine Upregulation of FGF21

NCT ID: NCT02118142

Last Updated: 2014-08-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

23 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-03-31

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

People with poor insulin sensitivity do not respond normally to elevations in blood sugar. This may increase their risk of developing diabetes in the future. The purpose of this research study is to determine if the nutrient betaine, found in beets, spinach and wheat products, can enhance the production of fetal growth factor 21 (FGF21), a molecule that is believed to promote insulin sensitivity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

AIM: To determine if betaine is a modulator of FGF21 in humans. Low plasma betaine is associated with an increased risk of metabolic syndrome, but the mechanisms modulating this correlation are poorly delineated. Betaine bioavailability in humans is determined by dietary intake and genetic polymorphisms that influence betaine metabolism. Therefore, moderating betaine levels could be particularly beneficial for some individuals. FGF21 is elevated in response to insulin insensitivity and is under active investigation as a therapeutic modality. The mechanisms of action of FGF21 and betaine on insulin sensitivity in humans are incompletely understood. This study tests the hypothesis that betaine induces FGF21 secretion and insulin sensitizing actions in humans by measuring plasma FGF21, betaine, choline (betaine precursor), glucose, insulin and adiponectin in response to betaine supplementation over a 24 hour time course in 20 healthy, lean individuals. This pilot nutrition intervention will provide key preliminary evidence for understanding whether and how betaine exerts metabolic benefit in humans and will inform a future study to investigate the novel betaine-FGF21-insulin sensitivity axis in a larger cohort.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Insulin Sensitivity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Betaine

6 gram dose of betaine delivered in encapsulated form

Group Type ACTIVE_COMPARATOR

Betaine

Intervention Type DIETARY_SUPPLEMENT

6 gram one-time dose of betaine delivered in encapsulated form with an unsweetened beverage

Dextrose

6 gram dose of dextrose delivered in encapsulated form

Group Type PLACEBO_COMPARATOR

Dextrose

Intervention Type DIETARY_SUPPLEMENT

6 gram one-time dose of dextrose delivered in encapsulated form with an unsweetened beverage

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Betaine

6 gram one-time dose of betaine delivered in encapsulated form with an unsweetened beverage

Intervention Type DIETARY_SUPPLEMENT

Dextrose

6 gram one-time dose of dextrose delivered in encapsulated form with an unsweetened beverage

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy
* Able/willing to consume study meals
* Non-smoker
* BMI in normal range (18-24.9)

Exclusion Criteria

* Use of chronic medications
* Abnormal physical examination or chronic illness
* Use of drugs or medications known to alter choline/betaine metabolism
* Consumption of more than 2 oz of alcohol/day or 24 oz wine/day
* Use of choline/betaine-containing dietary supplements during the previous 3 months
* Diagnosed with Cystathionine Beta-Synthase (CBS) Deficiency
* Pregnant or breastfeeding
* Known hypersensitivity to betaine
* Current substance abuse or addiction
Minimum Eligible Age

21 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

UNC Nutrition Research Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Karen Corbin, PhD, RD

Role: PRINCIPAL_INVESTIGATOR

UNC Nutrition Research Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UNC Nutrition Research Institute

Kannapolis, North Carolina, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

13-2548

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.